Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 435

1.

Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.

Maeshima AM, Taniguchi H, Fukuhara S, Morikawa N, Munakata W, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Tsuda H.

Am J Surg Pathol. 2013 Apr;37(4):563-70. doi: 10.1097/PAS.0b013e3182759008.

PMID:
23426122
2.

Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment.

Miyoshi H, Arakawa F, Sato K, Kimura Y, Kiyasu J, Takeuchi M, Yoshida M, Ichikawa A, Ishibashi Y, Nakamura Y, Nakashima S, Niino D, Sugita Y, Ohshima K.

Cancer Sci. 2012 Aug;103(8):1567-73. doi: 10.1111/j.1349-7006.2012.02307.x. Epub 2012 May 17.

3.

CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.

Alvaro-Naranjo T, Jaén-Martínez J, Gumá-Padró J, Bosch-Príncep R, Salvadó-Usach MT.

Ann Hematol. 2003 Sep;82(9):585-8. Epub 2003 Jul 31.

PMID:
12898184
4.
5.

Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.

Maeshima AM, Taniguchi H, Nomoto J, Maruyama D, Kim SW, Watanabe T, Kobayashi Y, Tobinai K, Matsuno Y.

Cancer Sci. 2009 Jan;100(1):54-61. doi: 10.1111/j.1349-7006.2008.01005.x. Epub 2008 Nov 25.

6.

Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression.

Saito B, Shiozawa E, Yamochi-Onizuka T, Adachi D, Nakamaki T, Tomoyasu S, Omine M, Mitsuya T, Takimoto M, Ota H.

Pathol Int. 2004 Sep;54(9):667-74.

PMID:
15363034
7.

Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance.

Hiraga J, Tomita A, Sugimoto T, Shimada K, Ito M, Nakamura S, Kiyoi H, Kinoshita T, Naoe T.

Blood. 2009 May 14;113(20):4885-93. doi: 10.1182/blood-2008-08-175208. Epub 2009 Feb 26.

9.

[Richter syndrome: report of a case].

Chen DB, Song QJ, Shen DH.

Zhonghua Bing Li Xue Za Zhi. 2010 Jul;39(7):487-8. Chinese. No abstract available.

PMID:
21055184
10.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
11.

Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma.

Dzietczenia J, Wróbel T, Mazur G, Poreba R, Jaźwiec B, Kuliczkowski K.

Med Oncol. 2010 Sep;27(3):743-6. doi: 10.1007/s12032-009-9278-9. Epub 2009 Aug 7.

PMID:
19662541
12.

CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.

Bilić E, Femenić R, Konja J, Simat M, Dubravcić K, Batinić D, Ries S, Rajić L.

Coll Antropol. 2010 Mar;34(1):171-5.

PMID:
20432747
13.

Composite lymphoma of the orbit treated with rituximab.

Kang SJ, Schmack I, Wojno TH, Grossniklaus HE.

Ophthal Plast Reconstr Surg. 2007 Mar-Apr;23(2):143-4.

PMID:
17413631
14.

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.

Hohloch K, Sahlmann CO, Lakhani VJ, Wulf G, Glass B, Hasenkamp J, Meller J, Riggert J, Trümper L, Griesinger F.

Ann Hematol. 2011 Nov;90(11):1307-15. doi: 10.1007/s00277-011-1199-y. Epub 2011 Mar 1.

PMID:
21360108
15.

Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia.

D'Auria F, Guariglia R, Villani O, Mansueto G, Grieco V, Zonno A, Bianchino G, Di Giovannantonio L, Vita G, Musto P.

Clin Ther. 2010 Oct;32(11):1911-6. doi: 10.1016/j.clinthera.2010.10.005.

PMID:
21095486
16.

Polymerase chain reaction detection of cells carrying t(14;18) in bone marrow of patients with follicular and diffuse large B-cell lymphoma: the importance of analysis at diagnosis and significance of long-term follow-up.

Papajík T, Jedlicková K, Kriegová E, Jarosová M, Raida L, Faber E, Hubácek J, Vondráková J, Pikalová Z, Indrák K.

Neoplasma. 2001;48(6):501-5.

PMID:
11949845
17.

De novo diffuse large B-cell lymphoma with a CD20 immunohistochemistry-positive and flow cytometry-negative phenotype: molecular mechanisms and correlation with rituximab sensitivity.

Tokunaga T, Tomita A, Sugimoto K, Shimada K, Iriyama C, Hirose T, Shirahata-Adachi M, Suzuki Y, Mizuno H, Kiyoi H, Asano N, Nakamura S, Kinoshita T, Naoe T.

Cancer Sci. 2014 Jan;105(1):35-43. doi: 10.1111/cas.12307. Epub 2013 Dec 22.

19.

Predictive significance of the cut-off value of CD20 expression in patients with B-cell lymphoma.

Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B.

Oncol Rep. 2010 Oct;24(4):1101-7.

PMID:
20811695
20.

Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials.

Griffin MM, Morley N.

Expert Opin Biol Ther. 2013 May;13(5):803-11. doi: 10.1517/14712598.2013.786698. Review.

PMID:
23560506

Supplemental Content

Support Center